Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B v...

Full description

Saved in:
Bibliographic Details
Published in:JGH open 2021-11, Vol.5 (11), p.1275-1283
Main Authors: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Mitsuhashi, Takeshi, Hirao, Akihiro, Tanaka, Takahiro, Taniguchi, Tatsuya, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Format: Article
Language:English
Subjects:
Alcohol
atezolizumab
bevacizumab
Diabetes
Drug dosages
Etiology
Hepatitis B
Hepatitis C
Immunotherapy
Inflammation
Laboratories
lenvatinib
Liver cancer
Magnetic resonance imaging
Monoclonal antibodies
Original
Patients
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression‐free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174–0.602; P 
ISSN:2397-9070
2397-9070
DOI:10.1002/jgh3.12663